Please ensure Javascript is enabled for purposes of website accessibility
Home / Products / Antibody / Recombinant Antibody

Anti-Tau Antibody (N337/37)

Catalog #:   RHC82419 Specific References (50) DATASHEET
Host species: Mouse
Isotype: IgG2a, kappa
Applications: IHC, WB
Overview

Catalog No.

RHC82419

Host species

Mouse

Isotype

IgG2a, kappa

Clonality

Monoclonal

Target

MAPTL, Paired helical filament-tau, MTBT1, Microtubule-associated protein tau, TAU, Neurofibrillary tangle protein, MAPT, PHF-tau

Concentration

1 mg/ml

Endotoxin level

Please contact with the lab for this information.

Purity

>95% as determined by SDS-PAGE.

Purification

Protein A/G purified from cell culture supernatant.

Applications

IHC, WB

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.

Clone ID

N337/37

Data Image
References

Structural exposure of different microtubule binding domains determines the propagation and toxicity of pathogenic tau conformers in Alzheimer's disease., PMID:40512826

Unique lipid cargoes in APOE4 human brain-derived extracellular vesicles recruit cell adhesion molecules and promote tauopathy in Alzheimer's disease., PMID:40502793

The Neurofibrillary Tangle Maturity Scale: A Novel Framework for Tangle Pathology Evaluation in Alzheimer's Disease., PMID:40501844

Associations between temporal lobe cortical NODDI measures and memory function in individuals without clinical dementia., PMID:40501140

β-Amyloid as a new target to suppress tonic PTH hypersecretion in primary hyperparathyroidism., PMID:40492090

Translational Medicine in Alzheimer's Disease: The Journey of Donanemab From Discovery to Clinical Application., PMID:40486952

[Correlation between soluble CD146 and systemic vasculitis]., PMID:40484821

A novel pThr217 tau monoclonal antibody reveals neuropathological heterogeneity in tauopathies., PMID:40473739

Structures of Fab-stabilized CHIP reveal a conformational switch important in E3 ligase and chaperone functions., PMID:40463190

Synaptotoxic effects of extracellular tau are mediated by its microtubule-binding region., PMID:40455293

Research hotspots and trends in lung cancer immunotherapy are revealed by a bibliometric study spanning the years 2004 to 2024., PMID:40448551

Hippocampal subfields: volume, neuropathological vulnerability and cognitive decline in Alzheimer's and Parkinson's disease., PMID:40448161

Chimeric antigen receptors discriminate between tau and distinct amyloid-beta species., PMID:40448101

A 2025 update on treatment strategies for the Alzheimer's disease spectrum., PMID:40442885

Acute targeting of N-terminal tau protein has long-lasting beneficial effects in Tg2576 APP/Aβ mouse model by reducing cognitive impairment, cerebral Aβ-amyloidosis, synaptic remodeling and microgliosis later in life., PMID:40442822

Insights into pathophysiology, biomarkers, and therapeutics in tauopathies: Proceedings of the Tau2024 Global Conference., PMID:40437880

CSF proteomics of semorinemab Alzheimer's disease trials identifies cell-type specific signatures., PMID:40435316

Immunotherapy against tau fragment diminishes AD pathology, improving synaptic function and cognition., PMID:40426267

Lemborexant ameliorates tau-mediated sleep loss and neurodegeneration in males in a mouse model of tauopathy., PMID:40425791

Bispecific brain-penetrant antibodies for treatment of Alzheimer's disease., PMID:40425446

Nanoplatforms Targeting Intrinsically Disordered Protein Aggregation for Translational Neuroscience Applications., PMID:40423094

[Prospects for treating Alzheimer's disease]., PMID:40420451

Understanding the impact of amyloid beta targeted therapies on biomarkers and clinical endpoints in Alzheimer's disease., PMID:40417267

The NLRP3-P2X7 Axis and Cytokine Crosstalk in Alzheimer's Disease: Mechanisms, Implications, and Therapeutic Opportunities., PMID:40415299

Intracerebroventricular phospho-tau immunotherapy alleviates cortical phospho-tau burden and motor phenotype in a neuron-specific P301S tauopathy mouse., PMID:40403829

Fluid biomarkers in atypical Parkinsonism: current state and future perspectives., PMID:40392273

TRAILBLAZER-ALZ 4: A phase 3 trial comparing donanemab with aducanumab on amyloid plaque clearance in early, symptomatic Alzheimer's disease., PMID:40390253

Pittsburgh plasma p-tau217: classification accuracies for autosomal dominant and sporadic Alzheimer's disease in the community., PMID:40385398

Electro-Sensing Analysis for Parkinson's Disease Biomarker on Dual-Electrode Surface: Complemented by Molecular Docking., PMID:40384391

Anti-cis P-tau attenuates tauopathy and enhances cognitive function following global cerebral ischemia in mice., PMID:40378437

Development of Zn-Based Tower-like Photoelectrochemical Sensor Array for Sandwich-Type Immunosensing Analysis of Tau., PMID:40374565

A fully automated paper-based smartphone-assisted microfluidic chemiluminescence sample to result immunoassay platform., PMID:40374237

Alzheimer's Is a Multiform Disease of Sustained Neuronal Integrated Stress Response Driven by the C99 Fragment Generated Independently of AβPP; Proteolytic Production of Aβ Is Suppressed in AD-Affected Neurons: Evolution of a Theory., PMID:40362488

pS396/pS404 (PHF1) tau vaccine outperforms pS199/pS202 (AT8) in rTg4510 tauopathy model., PMID:40360566

High precision and cost-effective multiplex quantification of amyloid-β40, amyloid-β42, p181Tau, p217Tau, neurofilament light chain, and glial fibrillary acidic protein from plasma and serum., PMID:40356374

Structural and biochemical differences between non-catalytic and catalytic antibodies., PMID:40356286

Lecanemab Treatment in a Specialty Memory Clinic., PMID:40354064

[An Update on Hereditary Dementias]., PMID:40350628

N-glycosylation of PD-L1 modulates the efficacy of immune checkpoint blockades targeting PD-L1 and PD-1., PMID:40346531

Targeted proteomic biomarker profiling using NULISA in a cohort enriched with risk for Alzheimer's disease and related dementias., PMID:40318118

Alzheimer's disease patient brain extracts induce multiple pathologies in novel vascularized neuroimmune organoids for disease modeling and drug discovery., PMID:40316675

Soluble TREM-1 ameliorates gouty arthritis by selective inhibition of proinflammatory cytokines and chemokines without affecting TGFβ production., PMID:40314990

Uncertainties in anti-amyloid monoclonal antibody therapy for Alzheimer's disease: the challenges ahead., PMID:40314575

Comparison of ERlangen Score with pTau/Aβ1-42 Ratio for Predicting Cognitive Decline and Conversion to Alzheimer's Disease., PMID:40309797

A Novel Phosphorylated Tau Conformer Implicated in the Tauopathy Pathogenesis of Human Neurons., PMID:40305319

Facile generation of drug-like conformational antibodies specific for amyloid fibrils., PMID:40301692

Alzheimer's disease and the immune system: A comprehensive overview with a focus on B cells, humoral immunity, and immunotherapy., PMID:40297057

Interactions of Therapeutic Antibodies With Presynaptically-Released Misfolded Proteins in Neurodegenerative Diseases. A Spatial Monte-Carlo Simulation Study., PMID:40296445

Neurodegeneration and the immune system: lessons from autoimmune encephalitis., PMID:40274643

Cell-specific mitochondrial response in progressive supranuclear palsy., PMID:40254117

Datasheet

Document Download

Anti-Tau Antibody (N337/37).pdf

 

$ 328
Product specifications
100 μg 328 1 mg 1640

Contact Information

Order: order@antibodysystem.com

Mail: support@antibodysystem.com

Distributor list

For research use only. Not for human or drug use.

Need help with your order?

Find out more about placing an order here

Anti-Tau Antibody (N337/37) [RHC82419]
Terms of sale Website terms of use Cookie policy Privacy
Copyright © 2025 AntibodySystem SAS. All Rights Reserved.            All Products are for Research Use Only